The rest of this story is for members
The rest is for members
The story continues: the full timeline, the transaction ranges, and the names the forms carry.
Premium comes through the Telegram channel. Already have a code? Sign in to activate it.
Premium
CADL
Kendall: Jefferies sees almost 200% potential in the biotech company
Jefferies initiated coverage on biotech company Kendall (CADL) with a buy rating and a price target indicating a gap of almost 200% from the current price, following a successful trial in prostate cancer treatment.
Other Stories
RAPP: positive results, the stock plunged, and the CFO bought
InsidersRAPP2d ago3 min read
Arcus: analysts raise targets on a day of stock decline
PremiumAnalystsRCUS3d ago2 min read
Morning review: futures opened quietly and Brent retreated, and beneath the surface Friday was weak
PremiumMarket Overview2h ago3 min read